2,056 results match your criteria efficacy clarithromycin

Randomized clinical trial to compare the efficacy of ivermectin versus placebo to negativize nasopharyngeal PCR in patients with early COVID-19 in Peru (SAINT-Peru): a structured summary of a study protocol for randomized controlled trial.

Trials 2021 Apr 9;22(1):262. Epub 2021 Apr 9.

School of Public Health and Administration, Universidad Peruana Cayetano Heredia, Lima, Peru.

Objectives: The primary objective is to determine the effect of a daily dose of ivermectin administered in three consecutive days to non-severe COVID-19 patients with no more than 96 hours of symptoms, on the detection of SARS-CoV-2 RNA by PCR from nasopharyngeal swabs at day seven post-treatment initiation. The secondary objectives are: 1. To assess the efficacy of ivermectin to reduce the SARS-CoV-2 viral load in the nasopharyngeal swab on days 4, 7, 14 and 21 post-treatment initiation 2. Read More

View Article and Full-Text PDF

A Randomized Phase II Trial Comparing the Efficacy and Safety of Pioglitazone, Clarithromycin and Metronomic Low-Dose Chemotherapy with Single-Agent Nivolumab Therapy in Patients with Advanced Non-small Cell Lung Cancer Treated in Second or Further Line (ModuLung).

Front Pharmacol 2021 16;12:599598. Epub 2021 Mar 16.

Department of Internal Medicine III, Hematology and Oncology, University Hospital Regensburg, Regensburg, Germany.

Most non-small cell lung cancers occur in elderly and frequently comorbid patients. Therefore, it is necessary to evaluate the efficacy of biomodulatory active therapy regimen, concertedly interfering with tumor-associated homeostatic pathways to achieve tumor control paralleled by modest toxicity profiles. The ModuLung trial is a national, multicentre, prospective, open-label, randomized phase II trial in patients with histologically confirmed stage IIIB/IV squamous ( = 11) and non-squamous non-small cell ( = 26) lung cancer who failed first-line platinum-based chemotherapy. Read More

View Article and Full-Text PDF

Eradication Rates for Esomeprazole and Lansoprazole-Based 7-Day Non-Bismuth Concomitant Quadruple Therapy for First-Line Anti- Treatment in Real World Clinical Practice.

Infect Drug Resist 2021 25;14:1239-1246. Epub 2021 Mar 25.

Division of Hepatogastroenterology, Department of Internal Medicine, Chang Gung Memorial Hospital, Kaohsiung, Taiwan.

Purpose: Non-bismuth concomitant quadruple therapy is commonly administered in Taiwan, achieving an acceptable efficacy as a first-line anti treatment. This study compared the eradication rates between esomeprazole- and lansoprazole-based non-bismuth concomitant quadruple therapy for first-line anti- treatment.

Patients And Methods: This study included 206 -infected naïve patients between July 2016 and February 2019. Read More

View Article and Full-Text PDF

Treatment of Refractory Infection-Tailored or Empirical Therapy.

Gut Liver 2021 Mar 31. Epub 2021 Mar 31.

Division of Gastroenterology and Hepatology, Department of Internal Medicine, National Taiwan University Hospital, Taipei, Taiwan.

The treatment of refractory remains challenging in clinical practice. Factors that should be considered in the treatment of refractory infection include treatment length, dosage of antibiotics and proton pump inhibitors (PPIs), number of drugs, and the selection of appropriate antibiotics. Extending the treatment length of triple therapy and non-bismuth quadruple therapy to 14 days may increase the eradication rate compared with a shorter period (7 or 10 days). Read More

View Article and Full-Text PDF

Clarithromycin as an adjunct to periodontal therapy: a systematic review and meta-analysis.

Int J Dent Hyg 2021 Mar 26. Epub 2021 Mar 26.

School of Dentistry, University of Birmingham, Birmingham, United Kingdom.

Objective: To collate the literature evaluating the efficacy of clarithromycin as an adjunct to non-surgical periodontal therapy, and conduct meta-analyses for changes in probing pocket depth (PPD) and clinical attachment level (CAL).

Methods: Five electronic databases were searched from inception to May 2020 (PubMed, Cochrane CENTRAL, EMBASE via OVID, Web of Science, OpenGrey). Clinical outcomes were extracted, pooled, and meta-analyses conducted using mean difference with standard deviations. Read More

View Article and Full-Text PDF

Case Report: Successful Treatment of Cutaneous Squamous Cell Carcinoma in Three Patients With a Combination of Acitretin and Clarithromycin.

Front Oncol 2021 26;11:650974. Epub 2021 Feb 26.

Department of Dermatology, The First Affiliated Hospital of Fujian Medical University, Fuzhou, China.

Few studies have evaluated acitretin as a primary treatment for cutaneous squamous cell carcinoma (CSCC). We report, for the first time, three cases of CSCC successfully treated with acitretin and clarithromycin. A literature review on this subject was also was performed. Read More

View Article and Full-Text PDF
February 2021

antimicrobial resistance and gene variants in high and low gastric cancer risk populations.

J Clin Microbiol 2021 Mar 10. Epub 2021 Mar 10.

Division of Comparative Medicine, Massachusetts Institute of Technology, Cambridge, MA

Colombia, South America has one of the world's highest burdens of infection and gastric cancer. While multi-drug antibiotic regimens can effectively eradicate , treatment efficacy is being jeopardized by the emergence of antibiotic-resistant strains. Moreover, the spectrum of and genetic mechanisms for antibiotic resistance in Colombia is under reported. Read More

View Article and Full-Text PDF

Clarithromycin versus furazolidone for naïve Helicobacter pylori infected patients in a high clarithromycin resistance area.

J Gastroenterol Hepatol 2021 Mar 10. Epub 2021 Mar 10.

Department of Gastroenterology, Qilu Hospital, Cheeloo College of Medicine, Shandong University, Jinan, Shandong, China.

Background And Aim: The increase in antibiotic resistance makes the eradication of Helicobacter pylori more difficult. Considering the limitations of the application of susceptibility-guided therapy, it is important to find an effective empirical regimen. The aim of the study is to compare the efficacy, safety, and cost-effectiveness of clarithromycin-based bismuth-containing quadruple therapy (C-BQT) and furazolidone-based bismuth-containing quadruple therapy (F-BQT) in naïve H. Read More

View Article and Full-Text PDF

In Vitro Effects of LN66 and Antibiotics Used Alone or in Combination on Mature Biofilm.

Jianfu Ji Hong Yang

Microorganisms 2021 Feb 18;9(2). Epub 2021 Feb 18.

State Key Laboratory of Microbial Metabolism, School of Life Sciences and Biotechnology, Shanghai Jiao Tong University, Shanghai 201100, China.

is a gastrointestinal pathogen with high prevalence that harms human health. Studies have shown that can form antibiotic-tolerant biofilms, which may interfere with the efficacy of clinical antibiotic therapy. Probiotics can antagonize planktonic and biofilm pathogen cells and thus may play an auxiliary role in antibiotic therapy. Read More

View Article and Full-Text PDF
February 2021

Ten-day bismuth-containing quadruple therapy versus 7-day proton pump inhibitor-clarithromycin containing triple therapy as first-line empirical therapy for the Helicobacter pylori infection in Korea: a randomized open-label trial.

BMC Gastroenterol 2021 Mar 2;21(1):95. Epub 2021 Mar 2.

Center for Gastric Cancer, National Cancer Center, 323 Ilsan-ro, Ilsandong-gu, Goyang, Gyeonggi, 10408, South Korea.

Background: This randomized, open-label trial aimed to compare the efficacy of 10-day bismuth-containing quadruple therapy (BQT) with 7-day proton-pump inhibitor-clarithromycin containing standard triple therapy (STT) as an empirical first-line Helicobacter pylori therapy.

Methods: Participants with H. pylori infection were randomly assigned to either 10-day BQT (daily doses of bismuth 300 mg, four times; lansoprazole 30 mg, twice; metronidazole 500 mg, three times; and tetracycline 500 mg, four times) or 7-day STT (lansoprazole 30 mg; amoxicillin 1,000 mg; and clarithromycin 500 mg; each given twice daily). Read More

View Article and Full-Text PDF

Efficacy of bismuth added to standard triple therapy as the first-line eradication regimen for Helicobacter pylori infection.

Helicobacter 2021 Mar 1:e12792. Epub 2021 Mar 1.

Department of Internal Medicine, St. Vincent Hospital, The Catholic University of Korea College of Medicine, Seoul, South Korea.

Background: Addressing the increasing antibiotic resistance, including clarithromycin resistance, which affects Helicobacter pylori eradication therapy, is a challenge for clinicians. The objective of this study was to determine the efficacy of bismuth added to standard triple therapy as a first-line treatment regimen for Helicobacter pylori infection. The secondary outcome was the treatment efficacy for clarithromycin-resistant strains. Read More

View Article and Full-Text PDF

[Helicobacter pylori: When to look for an infection and treat it in adults?]

J-D de Korwin

Rev Med Interne 2021 Feb 26. Epub 2021 Feb 26.

Université de Lorraine, CHRU-Nancy, département de médecine interne et immunologie clinique-BPC, rue du Morvan, 54511 Vandœuvre-Lès-Nancy cedex, France. Electronic address:

Helicobacter pylori infection is acquired during childhood mainly within the family. It causes active chronic gastritis associated with the development of many digestive and extra digestive diseases. Its expression results from interactions between the bacteria, the host and environmental factors modulating the evolution of gastritis and acid secretion. Read More

View Article and Full-Text PDF
February 2021

Gastric Acid Powered Nanomotors Release Antibiotics for In Vivo Treatment of Helicobacter pylori Infection.

Small 2021 Mar 23;17(11):e2006877. Epub 2021 Feb 23.

State Key Laboratory of Agriculture Microbiology, College of Life Science and Technology, Huazhong Agricultural University, Wuhan, 430070, China.

Helicobacter pylori (H. pylori) infection has ≈75% probability of causing gastric cancer, so it is considered to be the strongest single risk factor for gastric malignancies. However, the harsh gastric acid environment has created obstacles to medical treatment. Read More

View Article and Full-Text PDF

Heterogeneity of Strains Isolated from Patients with Gastric Disorders in Guiyang, China.

Infect Drug Resist 2021 11;14:535-545. Epub 2021 Feb 11.

Key Laboratory of Microbiology and Parasitology of Education Department of Guizhou, School of Basic Medical Science, Guizhou Medical University/Joint Laboratory of Helicobacter Pylori and Intestinal Microecology of Affiliated Hospital of Guizhou Medical University, Guiyang, People's Republic of China.

Purpose: Chronic infection causes peptic ulcers in a subpopulation of individuals and is a risk factor for the development of gastric cancer. Multiple infections and heteroresistant contribute to poor treatment efficacy. Here, we investigated the extent of genetic diversity among strains within a given host and its influence on the results of antibiotic (metronidazole, levofloxacin, clarithromycin, amoxicillin, and tetracycline) susceptibility testing. Read More

View Article and Full-Text PDF
February 2021

Preliminary single-center experience of Helicobacter pylori eradication among the liver transplant recipients.

Helicobacter 2021 Feb 18:e12791. Epub 2021 Feb 18.

Division of Hepatology, Liver Disease Center, The Affiliated Hospital of Qingdao University, Qingdao, China.

Objective: To investigate the prevalence of Helicobacter pylori infection among orthotopic liver transplant (LT) recipients and explore the efficacy and safety of H. pylori eradication therapy.

Methods: Liver transplant recipients receiving regular follow-up in our center were assessed by 13C-urea breath test between February 2018 and July 2020. Read More

View Article and Full-Text PDF
February 2021

Investigating the Efficacy of Triple Drug Therapy and Sequential Drug Therapy in the Eradication of Helicobacter Pylori with Respect to Antigen Stool test: A Pilot Study.

Kathmandu Univ Med J (KUMJ) 2020 Jan.-Mar;18(69):74-83

Pharmacovigillance Unit/ Research and Development Division, Dhulikhel Hospital, Kathmandu University Hospital, Dhulikhel, Kavre.

Background Helicobacter pylori is one of the most prevalent infectious disease worldwide. The treatment regimens involve mainly two therapies: Standard Triple drug therapy and Sequential drug therapy. Several studies have shown that the sequential therapy has higher eradication rates of H. Read More

View Article and Full-Text PDF
February 2021

Efficacy and Safety of Antofloxacin-Based Triple Therapy for Helicobacter pylori Eradication Failure in China.

Dig Dis Sci 2021 Feb 8. Epub 2021 Feb 8.

Department of Digestive Diseases, 900TH Hospital of Joint Logistics Support Force, 156 North Road of West No.2 Ring, Fuzhou, 350025, China.

Aims: Quinolone-containing triple therapy has been considered as the second-line therapy for eradication of Helicobacter pylori (H. pylori). At present, there are no data to show the efficacy and safety of antofloxacin-based rescue therapy for the eradication of H. Read More

View Article and Full-Text PDF
February 2021

Reverse hybrid therapy for Helicobacter pylori eradication: A systematic review and meta-analysis.

Helicobacter 2021 Apr 3;26(2):e12784. Epub 2021 Feb 3.

Department of Gastroenterology, The First Affiliated Hospital of Nanchang University, Nanchang, China.

Background: The efficacy and safety of reverse hybrid therapy in the treatment of Helicobacter pylori (H. pylori) infection remained unclear.

Materials And Methods: This systematic review was performed in accordance with the PRISMA 2009 guidelines. Read More

View Article and Full-Text PDF

Amoxicillin and Clarithromycin Mucoadhesive Delivery System for Infection in a Mouse Model: Characterization, Pharmacokinetics, and Efficacy.

Pharmaceutics 2021 Jan 24;13(2). Epub 2021 Jan 24.

Reig Jofre Laboratories, Avda dels Flors s/n, 08970 Sant Joan Despi, Spain.

is the main pathogen responsible for gastric ulcers and a predisposing factor of stomach cancer. Although current treatment is usually successful, it requires high doses and frequent administration. An innovative mucoadhesive system (Mucolast) loaded with amoxicillin and clarithromycin is proposed to improve the efficacy of treatment against . Read More

View Article and Full-Text PDF
January 2021

Safety and Efficacy of Nitazoxanide-Based Regimen for the Eradication of Infection: A Systematic Review and Meta-Analysis.

Gastroenterology Res 2020 Dec 23;13(6):260-268. Epub 2020 Dec 23.

Division of Gastroenterology and Hepatology, Geisinger Medical Center, Danville, PA 17822, USA.

Background: (HP) is the most common cause of gastritis worldwide. Clarithromycin-based triple therapy or bismuth-based quadruple therapy is usually considered the first-line treatment, however with around 30% failure rate for both regimens. Drug resistance of clarithromycin and metronidazole is a growing concern in some parts of the world. Read More

View Article and Full-Text PDF
December 2020

Resumption/efficacy and safety of an azithromycin-containing regimen against Mycobacterium avium complex lung disease in patients who experienced adverse effects with a clarithromycin-containing regimen.

Respir Investig 2021 Mar 9;59(2):212-217. Epub 2021 Jan 9.

Department of Internal Medicine, National Hospital Organization Kinki-Chuo Chest Medical Center, Japan.

Background: Antibiotic therapy, including clarithromycin (CLR), has been widely used for the management of Mycobacterium avium complex (MAC) lung disease in clinical settings. When patients develop adverse events (AEs) during CLR-based treatment, the treatment regimen is modified or chemotherapy itself is discontinued. The need for alternative macrolide treatment strategies is emphasized due to the high rate of AEs possibly caused by CLR. Read More

View Article and Full-Text PDF

Dual Clarithromycin and Metronidazole Resistance is the Main Cause of Failure in Ultimate Helicobacter pylori Eradication.

Dig Dis 2021 Jan 11. Epub 2021 Jan 11.

Background/aim: Antimicrobial resistance significantly affects the cure rate of Helicobacter pylori (H. pylori) eradication. We evaluated the risk factor of failure in ultimate H. Read More

View Article and Full-Text PDF
January 2021

The influence of P-glycoprotein expression in the standard treatment of Helicobacter pylori infection in Sprague Dawley rats.

Daru 2021 Jan 6. Epub 2021 Jan 6.

Drug and Herbal Research Centre, Faculty of Pharmacy, Universiti Kebangsaan Malaysia, Kuala Lumpur, Malaysia.

Background: P-glycoprotein (P-gp) is an Adenosine triphosphate (ATP) dependent drug-efflux pump which is located abundantly in the stomach and protects the gut mucosa from xenobiotic.

Objective: The purpose of this study was to investigate the influence of P-gp modulation on the efficacy of treatment regimen.

Method: P-gp modulation in rats was performed by using P-gp inducer (150 mg/kg rifampicin) and P-gp inhibitor (10 mg/kg cyclosporine A) for 14 days prior to be infected with Helicobacter pylori (H. Read More

View Article and Full-Text PDF
January 2021

Comparing the Efficacy of Sequential and Standard Quadruple Therapy for Eradication of H. Pylori Infection.

Acta Medica (Hradec Kralove) 2020 ;63(4):183-187

Department of Internal Medicine, Faculty of Medicine, Kashan University of Medical Sciences, Kashan, Iran.

Background: The aim of this study was comparison the effectiveness of sequential and standard quadruple therapy on eradication of H. pylori infection.

Methods: This clinical trial study was conducted on 160 patients with dyspepsia or gastroduodenal ulcer. Read More

View Article and Full-Text PDF
January 2020

Clinical and Biological Markers Predict the Efficacy of Glucocorticoid- and Macrolide-Based Postoperative Therapy in Patients With Chronic Rhinosinusitis.

Am J Rhinol Allergy 2020 Dec 21:1945892420982236. Epub 2020 Dec 21.

Department of Otolaryngology-Head and Neck Surgery, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, P.R. China.

Background: Although subsequent anti-inflammatory treatments are indispensable for patients with chronic rhinosinusitis (CRS) undergoing sinus surgery, few studies have explored the factors influencing the efficacy of postoperative anti-inflammatory treatment.

Objective: We aimed to develop prediction models for the response to glucocorticoid- and macrolide-based postoperative therapy in CRS patients.

Methods: We performed a post-hoc analysis of our previous study comparing the efficacy of fluticasone propionate and clarithromycin in the postoperative treatment of CRS patients. Read More

View Article and Full-Text PDF
December 2020

[European Registry on the management of Helicobacter pylori infection: features of diagnosis and treatment in Kazan].

Ter Arkh 2020 Sep 3;92(8):52-59. Epub 2020 Sep 3.

Gastroenterology Unit, Hospital Universitario de La Princesa, Instituto de Investigación Sanitaria Princesa (IIS-IP), Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBERehd), and Universidad Autónoma de Madrid (UAM).

Background: As part of an observational multicenter prospective study European Registry on the management of Helicobacter pylori infection, conducted on the initiative of the European H. pylori and Microbiota Study Group, the compliance of clinical practice in the management of patients with Helicobacter pylori infection in Kazan with clinical guidelines was assessed.

Materials And Methods: The data of 437 patients included into the register by clinical sites in Kazan in 20132019 were analyzed. Read More

View Article and Full-Text PDF
September 2020

Efficacy and safety of 7 days versus 10 days triple therapy based on levofloxacin-dexlansoprazole for eradication of : A pilot randomized trial.

Indian J Pharmacol 2020 Sep-Oct;52(5):356-364

Department of Biochemistry, Faculty of Pharmacy, Damanhour University, Damanhour, Egypt.

Background: Levofloxacin-based triple therapies are considered the standard regimen for eradication of Helicobacter pylori (H. pylori) due to decreased sensitivity to clarithromycin and the optimal duration of therapy is still controversial. Besides, there is no complete evidence about dexlansoprazole efficacy in the eradication of H. Read More

View Article and Full-Text PDF
December 2020

Meta-analysis of fluoroquinolones versus macrolides for treatment of legionella pneumonia.

J Infect Chemother 2021 Mar 23;27(3):424-433. Epub 2020 Oct 23.

Department of Clinical Infectious Diseases, Aichi Medical University, Aichi, Japan. Electronic address:

Background: Only a single meta-analysis has reported the clinical benefit of fluoroquinolones (FQs) for Legionella pneumonia; however, there is no robust data available to confirm this result, based on current guidelines.

Methods: We performed a systematic review and meta-analysis comparing FQs with macrolides (MCs) on their efficacy and safety in Legionella pneumonia, using studies published until January 2020. The outcomes included mortality (overall; 30-day), clinical cure, time to apyrexia, length of hospital stay, and adverse events. Read More

View Article and Full-Text PDF

Efficacy and safety of bismuth-containing quadruple treatment and concomitant treatment for first-line Helicobacter pylori eradication: A systematic review and meta-analysis.

Microb Pathog 2021 Mar 27;152:104661. Epub 2020 Nov 27.

Department of Epidemiology and Biostatistics, School of Public Health, Anhui Medical University, Hefei, Anhui, China. Electronic address:

Bismuth-containing quadruple treatment (BQT) and concomitant treatment (CT) were recommended as alternative first-line treatments of Helicobacter pylori (H. Pylori). A meta-analysis was performed to evaluate the cure rates and compare efficacy and safety of BQT and CT for H. Read More

View Article and Full-Text PDF